PhaseV Unveils AI-Powered Platform to Accelerate IBD Clinical Trials Through Predictive Site Selection
核心洞察
PhaseV (搜索) presented new study results at the 2026 Crohn's & Colitis (搜索) Congress demonstrating how AI-driven site selection and real-time analytics improve inflammatory bowel disease (搜索) trial efficiency.
The company's ClinOps Optimizer uses causal machine learning to model patient and site covariates, enabling sponsors to predict recruitment success and optimize site performance in real-time.
PhaseV (搜索)'s platform has delivered significant ROI for over 40 pharma and biotech sponsors, reducing trial costs by up to 50% and increasing probability of success by over 30%.
PhaseV (搜索) presented groundbreaking study results at the 2026 Crohn's & Colitis (搜索) Congress in Las Vegas, demonstrating how artificial intelligence and causal machine learning can transform inflammatory bowel disease (搜索) clinical trial execution. The Boston-based company's presentation, titled "AI and Causal ML Driven Site Selection and Real-Time Analytics for Clinical Trial Execution in Inflammatory Bowel Disease," showcased solutions addressing the primary drivers of trial delays including unpredictable patient recruitment, variability in clinical practice across sites, and limited agility in responding to protocol changes.
Strategic Partnership Enhances IBD Trial Optimization
PhaseV (搜索)'s IBD (搜索) offering is powered by a strategic collaboration with the Crohn's & Colitis Foundation (搜索), integrating insights from the Foundation's IBD Plexus Research Accelerator. This partnership provides access to the world's most comprehensive IBD patient data and biosample collection, enabling precise analyses that streamline site-to-protocol matching and identify optimal designs for complex IBD studies.
"Our solution shifts clinical operations from reactive monitoring to dynamic trial optimization," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV (搜索). "By applying causal ML to granular patient- and site-level data, we allow sponsors to treat every covariate as an operational lever. For Pharma and CRO partners, this means the ability to de-risk recruitment and optimize site performance in real-time, ensuring trials are not just managed, but mathematically steered toward successful outcomes."
Advanced Modeling Capabilities Drive Site Selection
The ClinOps Optimizer improves clinical trial site selection by modeling multiple covariates including age, BMI, ethnicity, genomic markers, comorbidities, and treatment history. Using causal machine learning, the platform enables sponsors to estimate each site's likelihood of achieving recruitment targets and data quality outcomes. This approach ensures site selection aligns with trial inclusion and exclusion criteria and therapeutic mechanism of action, supporting both population diversity and operational efficiency.
Real-Time Analytics Address IBD Trial Complexities
PhaseV (搜索) provides an interactive dashboard for continuous oversight of screening rates, visit adherence, and protocol deviations. This real-time visibility proves critical in IBD (搜索) research, where heterogeneous disease presentation and fluctuating patient conditions demand adaptive strategies. The platform's ability to provide dynamic trial optimization represents a significant advancement over traditional reactive monitoring approaches.
Expanding Market Presence and Proven Results
PhaseV (搜索) continues expanding its gastrointestinal footprint through collaborations with the Crohn's & Colitis Foundation (搜索) and strategic partnership with Alimentiv (搜索), a global GI contract research organization. The company currently supports more than 40 global pharma and biotech sponsors and CROs in optimizing clinical development across multiple therapeutic areas.
The company's integrated, multi-modal AI/ML platform optimizes every phase of the clinical trial lifecycle through core solutions including ClinOps, Trial, Portfolio, and Response Optimizers. These tools enable biopharma sponsors and CROs to select optimal assets, indications, and patient populations while rapidly designing, planning, and executing optimized fixed, Bayesian, and adaptive trials.
PhaseV (搜索)'s data-driven solutions have delivered significant return on investment for leading pharmaceutical and biotechnology sponsors, reducing trial costs by up to 50% and increasing the probability of success by over 30% across multiple therapeutic areas.